AzTrials
AzTrials

Adrenal TumorCRISALNCT06520111

CRISAL Study:Cancer Risk In Secreting Adrenal Lesions

An observational study of Adrenal Tumor and Adrenal Incidentaloma, run by University of Roma La Sapienza at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of the present study is to report the cancer risk in secreting adrenal lesions. Secondary aims: to compare the incidence of cancer in secreting versus non-secreting adrenal lesions, in order to evaluate whether adrenal hormone activity can be considered an independent predictive indicator of malignancy… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Adrenal Tumor, Adrenal Incidentaloma, Surgery
How many people
300 participants
Where
1 siteItaly
Study dates
27 Aug 2024to 10 Nov 2024
How long will I take part?
12 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: This is an ambispective (retrospective and prospective) multicentre observational study. It will based on the consecutive enrollment of all patients aged 18 years or over undergoing elective adrenalectomy, after the acceptance of informed consent. For the primary aim of the study, only patients affected by secreting adrenal lesion will be considered and the incidence of cancer will be established on the basis of the definitive histology. For the further aims of the study, all enrolled patients will be divided into: patients with secreting adrenal lesions and patients with non-secreting adrenal lesions. Both groups will be stratified on the basis of definitive histology (malignant/benign) in order to identify the incidence of cancer for each group, the results will then be compared within and postoperative at 30 days.

Who may be able to join

  • Patients undergoing elective adrenalectomy;
  • Patients aged ≥ 18 years
  • Acceptance of informed consent

Who cannot join

  • Patients undergoing emergency adrenalectomy;
  • Patients aged ≤ 18 years
  • Pregnant patients

Trial locations and contacts

1 site in 1 country.

Italy1 site, 1 recruiting
  • General and Mininvasive Surgery Department, Pederzoli Hospital,

    Peschiera del Garda, Verona, Italy.

    Marco Inama

    Recruiting

Other trials in Italy

About this study

The aim of the present study is to report the cancer risk in secreting adrenal lesions. Secondary aims: to compare the incidence of cancer in secreting versus non-secreting adrenal lesions, in order to evaluate whether adrenal hormone activity can be considered an independent predictive indicator of malignancy; compare intraoperative and 30-day postoperative outcomes of patients undergoing adrenalectomy for secreting adrenal lesions versus non-secretoring lesions; regardless of the type of adrenal lesion, identify if there is one MIS adrenal approach that is superior to the others in terms of intra- and postoperative outcomes.

Read the detailed description

Background: The risk of adrenal cancer increases with increasing lesion size. Up to 60% of malignant adrenal lesions have hormonal activity and that hypercortisolism is strongly suggestive of malignancy, however data regarding the risk of cancer risk in secreting adrenal lesions are not indicated.

Although guidelines suggest open adrenalectomy for lesions with preoperative features suspicious of malignancy (size ≥ 6 cm, radiological features suggestive of malignancy, history of neoplastic disease, rapid growth, several authors have reported the safety and feasibility of minimally invasive surgery (MIS) also in these cases.

Since no clear superiority of one MIS approach over another (lateral, posterior, or anterior approach) in terms of perioperative outcomes has been demonstrated, the guidelines agree on using the more familiar approach to the surgeon.

Knowing the oncological risk of adrenal secretion lesions could allow greater awareness in the patient's multidisciplinary approach and a better balance of the risk-benefit ratio in the choice of management of the patient affected by secreting adrenal lesion, especially in the case of asymptomatic lesion or manageable with medical therapy. Comparison of the various surgical approaches for the different types of adrenal lesions could allow identifying the best surgical route for each of them.

Methods: This study will be conducted in accordance with the principles of the Declaration of Helsinki and the guidelines for good clinical practice (ICH/GCP). The study protocol will be approved by the Ethics Committee of the institutions involved. An Institutional Data Safety Monitoring Board will also be appointed.This is an ambispective (retrospective and prospective) multicentre observational study. It will based on the consecutive enrollment of all patients aged 18 years or over undergoing elective adrenalectomy, after the acceptance of informed consent. For the primary aim of the study, only patients affected by secreting adrenal lesion will be considered and the incidence of cancer will be established on the basis of the definitive histology. For the further aims of the study, all enrolled patients will be divided into: patients with secreting adrenal lesions and patients with non-secreting adrenal lesions. Both groups will be stratified on the basis of definitive histology (malignant/benign) in order to identify the incidence of cancer for each group, the results will then be compared within and postoperative at 30 days. To assess the superiority of one approach over another, all patients will be stratified according to the minimally invasive approach adopted (anterior transperitoneal, lateral transperitoneal, lateral retroperitoneal, prone retroperitoneal, laparoscopic, robotic) and the type of adrenal pathology (secretory lesion, malignant tumor, metastasis, pheochromocytoma, etc…) and will be compared in terms of intra and 30 days postoperative results. All patients undergoing elective adrenalectomy aged ≥ 18 years will be included in the present study. Emergency cases and pregnant patients will be excluded.

The study involves the collection of the following data through the Redcap platform: patient demographic data, preoperative data (comorbidities and pharmacological therapies:, previous abdominal surgery, cancer history, lesion size and site, preoperative imaging and hormonal evaluation, American Society of Anaesthesiologists (ASA) class, Charlson comorbidity index (CCI) score), intraoperative data (surgical technique and surgical approach, trocar number, position and size in case of minimally invasive surgery, type of incision in case of open surgery, intraoperative complications, associated surgical procedures, conversion rate, operative time, intraoperative blood transfusions) and postoperative data (complications according to the Clavien-Dindo classification, re-intervention rate, postoperative stay, 30-day hospital readmission rate, 30 days-mortality, definitive histological examination, oncological results at follow up, participating center number of adrenalectomies by year, number of adrenalectomies per year performed by the operator.

Statistic analysis:A formal determination of the sample size was not carried out due to the ambispective observational nature of the study cohort and due to the absence in the literature of a common agreement on the incidence of cancer in patients with adrenal secreting lesions. Based on the case-series available from the SICE (Società Italiana di Chirurgia Endoscopica), a total recruitment capacity is estimated (summation of the number of patients per year per participating center), of about 300 patients.Categorical variables will be estimated as absolute and relative frequency, while continuous variables as median (IQR interquartile range). Inferential statistics for categorical variables will be estimated by Fisher exact test, while those of continuous variables by Mann-Whitney and Kruskal-Wallis tests (for independent data) and Wilcoxon and Friedman tests (for repeated data).

Institutional Review Boards. Authorship and publication: The rules described here apply to any presentation of this study. Members of the scientific committee qualify for the authorship of this study. Up to three authors per participating center can be entered into group authorship, which will be fully citable. The order of authors in the authorship group will be based on their active contribution to the study. Study results may be published and/or presented as final analyzes only after study completion. Publication and/or presentation means any paper, podium presentation, poster, abstract, or any other public presentation of this research. Data of each patient will be collected autonomously and anonymously by the single centers involved, using a common alphanumeric code decided by the coordinating centre. The collection of the aforementioned data will take place only after acceptance of the informed consent by the patient in accordance with the Declaration of Helsinki and after approval by the Ethics Committee of the proposing centre.

Keywords
cancer risk, adrenal surgery, secreting adrenal lesions
Medical subject headings
Adrenal Gland Neoplasms, Adrenal incidentaloma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06520111
Study groupRoleWhat they receive
patients underwent surgery for secreting adrenal lesionNot described
patients underwent surgery for non- secreting adrenal lesionNot described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cancer risk in secreting adrenal lesions.

    Number of patients who underwent adrenalectomy for secreting adrenal lesion which later proved to be malignant at definitive histological examination.

    This variable will be estimated as absolute and relative frequency and percentage value

    Measured: From July to December 2024

Secondary outcomes (3)
  1. Cancer risk in secreting versus non-secreting adrenal lesions

    Comparison between the incidence of cancer in patients affected by secreting adrenal lesions VS patients affected by non-secreting adrenal lesions.

    These two groups will be matched based on other preoperative characteristics (comorbidities and pharmacological therapies, cancer history, lesion size and site, preoperative imaging and hormonal evaluation) to reduce potential bias

    Categorical variables will be estimated as absolute and relative frequency, while continuous variables as median (IQR interquartile range). Inferential statistics for categorical variables will be estimated by Fisher exact test, while those of continuous variables by Mann-Whitney and Kruskal-Wallis tests (for independent data) and Wilcoxon and Friedman tests (for repeated data).

    Measured: From July to December 2024

  2. Intraoperative and postoperative outcomes of patients undergoing adrenalectomy for secreting adrenal lesions versus non-secreting lesions

    Comparison between intraoperative and 30-day postoperative outcomes of patients undergoing adrenalectomy for secreting adrenal lesions versus non-secretoring lesions.

    Categorical variables will be estimated as absolute and relative frequency, while continuous variables as median (IQR interquartile range). Inferential statistics for categorical variables will be estimated by Fisher exact test, while those of continuous variables by Mann-Whitney and Kruskal-Wallis tests (for independent data) and Wilcoxon and Friedman tests (for repeated data).

    Measured: From July to December 2024

  3. Intraoperative and postoperative outcomes in different minimally invasive adrenalectomies

    Comparison between the intraoperative and postoperative outcomes in different minimally invasive adrenalectomies (lateral, posterior, or anterior approach).

    Categorical variables will be estimated as absolute and relative frequency, while continuous variables as median (IQR interquartile range). Inferential statistics for categorical variables will be estimated by Fisher exact test, while those of continuous variables by Mann-Whitney and Kruskal-Wallis tests (for independent data) and Wilcoxon and Friedman tests (for repeated data).

    Measured: From July to December 2024

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jul 2024
  2. Study start27 Aug 2024 (estimated)
  3. Primary completion30 Sep 2024 (estimated)
  4. Study completion10 Nov 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
300 participants (estimated)
Target duration
12 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT06520111
Sponsor's protocol ID
CRISAL (4051 CESC)
Acronym
CRISAL
Status last verified
Aug 2024
First submitted
18 Jun 2024
Last updated
30 Aug 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: All IPD will be shared among other researchers involved in the study

Publications

  • Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B; German Adrenocortical Carcinoma Registry Group; European Network for the Study of Adrenal Tumors. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009 Jan 15;115(2):243-50. doi: 10.1002/cncr.24030.

    PubMed 19025987
  • Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8.

    PubMed 3558716
  • Birsen O, Akyuz M, Dural C, Aksoy E, Aliyev S, Mitchell J, Siperstein A, Berber E. A new risk stratification algorithm for the management of patients with adrenal incidentalomas. Surgery. 2014 Oct;156(4):959-65. doi: 10.1016/j.surg.2014.06.042.

    PubMed 25239353
  • Stefanidis D, Goldfarb M, Kercher KW, Hope WW, Richardson W, Fanelli RD; Society of Gastrointestinal and Endoscopic Surgeons. SAGES guidelines for minimally invasive treatment of adrenal pathology. Surg Endosc. 2013 Nov;27(11):3960-80. doi: 10.1007/s00464-013-3169-z. Epub 2013 Sep 10. No abstract available.

    PubMed 24018761
  • Kazaure HS, Sosa JA. Volume-outcome relationship in adrenal surgery: A review of existing literature. Best Pract Res Clin Endocrinol Metab. 2019 Oct;33(5):101296. doi: 10.1016/j.beem.2019.101296. Epub 2019 Jul 12.

    PubMed 31331729
  • undefined

  • Bergamini C, Martellucci J, Tozzi F, Valeri A. Complications in laparoscopic adrenalectomy: the value of experience. Surg Endosc. 2011 Dec;25(12):3845-51. doi: 10.1007/s00464-011-1804-0. Epub 2011 Jun 17.

    PubMed 21681621
  • Kahramangil B, Kose E, Remer EM, Reynolds JP, Stein R, Rini B, Siperstein A, Berber E. A Modern Assessment of Cancer Risk in Adrenal Incidentalomas: Analysis of 2219 Patients. Ann Surg. 2022 Jan 1;275(1):e238-e244. doi: 10.1097/SLA.0000000000004048.

    PubMed 32541223
  • Balla A, Corallino D, Ortenzi M, Palmieri L, Meoli F, Guerrieri M, Paganini AM. Cancer risk in adrenalectomy: are adrenal lesions equal or more than 4 cm a contraindication for laparoscopy? Surg Endosc. 2022 Feb;36(2):1131-1142. doi: 10.1007/s00464-021-08380-7. Epub 2021 Mar 1.

    PubMed 33650006
  • Castillo OA, Vitagliano G, Secin FP, Kerkebe M, Arellano L. Laparoscopic adrenalectomy for adrenal masses: does size matter? Urology. 2008 Jun;71(6):1138-41. doi: 10.1016/j.urology.2007.12.019. Epub 2008 Mar 12.

    PubMed 18336879

Questions about this trial

What is this clinical trial studying?

An observational study of Adrenal Tumor and Adrenal Incidentaloma, run by University of Roma La Sapienza at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 30 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Diletta D Corallino (+39-3888592412, diletta.corallino1989@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cancer risk in secreting adrenal lesions. (time frame: From July to December 2024). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06520111, which also lists 10 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Aug 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in